1. Health and quality of life in patients with relapsing multiple sclerosis: making the intangible tangible 
Howard Zwibel 
Journal of the Neurological Sciences 
Volume 287, Pages S11-S16 (December 2009)
DOI: /S X(09)71295-X
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Fig. 2
Proportion of multiple sclerosis treated with glatiramer acetate reaching three EDSS thresholds after ten years. Light blue: all patients (mITT population); dark blue: patients continuously taking glatiramer acetate for ten years (Ongoing population); grey: patients who had discontinued glatiramer acetate at long term follow-up (Withdrawn with LTFU population).
Data are taken from Ford et al. [11].
Journal of the Neurological Sciences  , S11-S16DOI: ( /S X(09)71295-X)
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Fig. 3
Work time loss vs. untreated patients for the 12 months that included the diagnosis of MS. White: interferon-β 1a im; grey: interferon-β 1b sc; black: glatiramer acetate. Data are taken from Lage et al. [22]. Short-term disability refers to extended time (e.g. >7 consecutive days) missed from work for non-work-related illness or injury when an official insurance claim was issued. Worker's compensation refers to time missed from work for work-related illness or injury when an official insurance claim was issued. Absenteeism refers to time missed from work for any reason other than Short-Term Disability and Worker's Compensation, including occasional sick days and vacation.
Journal of the Neurological Sciences  , S11-S16DOI: ( /S X(09)71295-X)
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Fig. 4
Evolution of depressive symptoms following initiation of treatment with interferon-β 1a im. Open squares: patients with depressed symptoms before treatment; solid squares: patients without depressed symptoms before treatment.
Data are taken from Mohr et al [28].
Journal of the Neurological Sciences  , S11-S16DOI: ( /S X(09)71295-X)
Copyright © 2009 Elsevier Ltd Terms and Conditions

5. Fig. 5
Evolution of fatigue impact following initiation of treatment with interferon-β (light shading) or glatiramer acetate (dark shading).
Data are taken from Metz et al [46].
Journal of the Neurological Sciences  , S11-S16DOI: ( /S X(09)71295-X)
Copyright © 2009 Elsevier Ltd Terms and Conditions

6. Fig. 6
Impact on days missed work following initiation of treatment with glatiramer acetate. Data represent the number of patients missing work in the three months preceding treatment initiation (light shading) and during twelve months of treatment (dark shading).
Data are taken from Ziemssen et al [44].
Journal of the Neurological Sciences  , S11-S16DOI: ( /S X(09)71295-X)
Copyright © 2009 Elsevier Ltd Terms and Conditions